Movement Alert｜Twist Bioscience Corp Intraday Rise 5.27% in Regular Trading, Analyst Initiations and Lilly TuneLab Collaboration Support Attention

Market Focus10-26

On October 26, Twist Bioscience Corp rose 5.27% in regular trading, trading at $147.25/share, with turnover of $57.5042 million.

The move coincided with continued market attention on recent analyst coverage and the company’s previously announced collaboration with Eli Lilly’s TuneLab on antibody characterization data services for AI-enabled drug discovery.

Jefferies initiated coverage on October 8 with a Hold rating and a $150 price target, while UBS initiated on September 9 with a Neutral rating and a $144 price target. Earlier, on September 16, Twist Bioscience Corp said it would provide antibody characterization data services to Lilly TuneLab, an AI/ML drug discovery platform created by Eli Lilly. These developments have kept investor focus on the company’s role in AI-assisted antibody discovery and near-term valuation expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment